sxc-2023
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 11, 2017 (NCT03301298)
Timeline
Indications
Mechanism of action
- Cystine/glutamate transporterACTIVATOR
SLC7A11 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sxc-2023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06343532 | Phase 1 | Jun 30, 2024 | Altasciences Company Inc., National Institute on Drug Abuse (NIDA), Promentis Pharmaceuticals, Inc. |
| NCT03887429 | Phase 2 | Mar 4, 2019 | Baylor University, Celerion, Promentis Pharmaceuticals, Inc. |
| NCT03797521 | Phase 2 | Dec 19, 2018 | Promentis Pharmaceuticals, Inc. |
| NCT03542435 | Phase 1 | Apr 26, 2018 | Promentis Pharmaceuticals, Inc. |
| NCT03301298 | Phase 1 | Sep 11, 2017 | Celerion, Promentis Pharmaceuticals, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Promentis Pharmaceuticals, Inc. | For profit | 5 | 4 | 2 | 2017 |
| Celerion | For profit | 2 | 0 | 2 | 2017 |
| Altasciences Company Inc. | For profit | 1 | 0 | 1 | 2024 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1